Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity. [PDF]
J Immunol, 2017 Nawaf MG +9 more
europepmc +1 more source
Targeting CD30L Alleviates Airway Remodeling via JNK/p38 MAPK Pathway in OVA-Induced Asthmatic Mice. [PDF]
Allergy Asthma Immunol ResXu C +15 more
europepmc +1 more source
Monoclonal Antibodies and Derivatives: Therapeutic Tools for Cancer. [PDF]
Oncol ResPoggi A.
europepmc +1 more source
Put the CAR-T before the HRS: Advances in Anti-CD30 Immunotherapy Targeting Hodgkin/Reed-Sternberg Cells in Classical Hodgkin Lymphoma. [PDF]
Oncol ResMayasin Y +8 more
europepmc +1 more source
Prognostic Value of Spatial and Topological Features of Tumor Microenvironment in Classic Hodgkin Lymphoma. [PDF]
Oncol ResBernal-Florindo I +9 more
europepmc +1 more source
CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro. [PDF]
Oncotarget, 2016 Hansen HP +17 more
europepmc +1 more source
The use of mass cytometry (CyTOF) to evaluate the cellular uptake of stable radiopharmaceutical surrogates in single cells: a proof-of-concept study. [PDF]
EJNMMI Radiopharm ChemGómez-Sánchez M +5 more
europepmc +1 more source
Nivolumab-Associated Cardiac Manifestation of Cutaneous T-Cell Lymphoma in a Patient With Concurrent Renal Cell Carcinoma. [PDF]
Mayo Clin Proc Innov Qual OutcomesIbrahim M +6 more
europepmc +1 more source